Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study.

"data availability . anonymized individual participant data and study documents can be requested for further research from www clinicalstudydatarequest com (study id 213569"

"Potential conflicts of interest. I. L. R. reports funding from Icosavax and Virometix to her institution for the conduct of RSV vaccine trials, and from GSK to her institution for conduct of this clinical trial. M. V. R. reports GSK funding to the Leuven University Vaccinology Center for the conduct of the clinical trial. C. Vm. reports GSK funding to her institution for the conduct of the clinical trial as at the time of the execution of the clinical trial she was an investigator; C. Vm. joined GSK after the close of the study at her institution and is currently an employee of GSK; however, she does not hold any shares. C. V. A., N. D. S., B. S., C. V., M. P. D., S. K., and V. H. were employees of GSK at the time of the study conduct.: N. D. S., B. S., M. P. D., C. V., S. K., and V. H. hold shares from GSK as part of their past/current employee remuneration. All current/previous employees of GSK declare financial and nonfinancial relationships and activities.: All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed."

"Financial support. This work was supported by GlaxoSmithKline Biologicals SA. GlaxoSmithKline Biologicals SA was involved in all stages of the study conduct and analysis and took responsibility for all costs associated with the development and the publishing of the article. Financial support ."

"Clinical Trials Registration NCT04657198; EudraCT, 2020-000692-21."